Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia
AGIOS PHARM (NASDAQ: AGIO) Delayed: 33.95 +0.88 (2.66%)
Previous Close $33.07    52 Week High $71.49 
Open $33.70    52 Week Low $33.50 
Day High $34.14    P/E N/A 
Day Low $33.30    EPS $-1.18 
Volume 884,551